Fuji Pharma Past Earnings Performance
Past criteria checks 4/6
Fuji Pharma has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 1.2% per year. Fuji Pharma's return on equity is 12.1%, and it has net margins of 12.2%.
Key information
2.5%
Earnings growth rate
9.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 1.2% |
| Return on equity | 12.1% |
| Net Margin | 12.2% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Fuji Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 41,639 | 5,060 | 9,180 | 3,184 |
| 30 Sep 23 | 40,889 | 3,435 | 8,331 | 3,184 |
| 30 Jun 23 | 38,438 | 2,036 | 8,939 | 2,485 |
| 31 Mar 23 | 36,925 | 2,634 | 8,191 | 2,485 |
| 31 Dec 22 | 35,976 | 2,692 | 7,756 | 2,485 |
| 30 Sep 22 | 35,426 | 2,696 | 7,355 | 2,485 |
| 30 Jun 22 | 34,962 | 2,433 | 8,353 | 2,446 |
| 31 Mar 22 | 34,439 | 2,245 | 8,326 | 2,446 |
| 31 Dec 21 | 34,141 | 2,222 | 8,446 | 2,446 |
| 30 Sep 21 | 33,990 | 2,432 | 8,340 | 2,446 |
| 30 Jun 21 | 34,392 | 3,161 | 6,821 | 3,060 |
| 31 Mar 21 | 34,165 | 3,796 | 7,111 | 3,060 |
| 31 Dec 20 | 34,120 | 2,668 | 7,371 | 3,060 |
| 30 Sep 20 | 33,793 | 2,085 | 8,048 | 3,060 |
| 30 Jun 20 | 33,854 | 2,006 | 9,500 | 2,052 |
| 31 Mar 20 | 34,701 | 1,577 | 9,417 | 2,052 |
| 31 Dec 19 | 34,968 | 2,611 | 9,076 | 2,052 |
| 30 Sep 19 | 36,279 | 2,962 | 8,957 | 2,052 |
| 30 Jun 19 | 37,361 | 3,287 | 8,922 | 1,760 |
| 31 Mar 19 | 38,431 | 3,324 | 8,864 | 1,760 |
| 31 Dec 18 | 38,231 | 3,167 | 9,093 | 1,760 |
| 30 Sep 18 | 37,909 | 3,372 | 9,054 | 1,760 |
| 30 Jun 18 | 37,243 | 3,219 | 8,935 | 1,825 |
| 31 Mar 18 | 36,024 | 3,255 | 8,644 | 1,825 |
| 31 Dec 17 | 36,412 | 3,525 | 8,297 | 1,825 |
| 30 Sep 17 | 35,387 | 3,301 | 7,859 | 1,825 |
| 30 Jun 17 | 35,217 | 3,141 | 7,567 | 1,840 |
| 31 Mar 17 | 34,717 | 2,835 | 7,344 | 1,840 |
| 31 Dec 16 | 34,234 | 2,650 | 7,172 | 1,840 |
| 30 Sep 16 | 34,229 | 2,118 | 7,416 | 1,840 |
| 30 Jun 16 | 33,708 | 2,354 | 7,041 | 1,729 |
| 31 Mar 16 | 33,056 | 2,293 | 7,177 | 1,729 |
| 31 Dec 15 | 32,540 | 2,121 | 7,473 | 1,729 |
| 30 Sep 15 | 31,680 | 2,092 | 7,227 | 1,729 |
| 30 Jun 15 | 31,254 | 2,030 | 7,458 | 1,769 |
| 31 Mar 15 | 30,497 | 1,947 | 7,265 | 1,769 |
| 31 Dec 14 | 30,378 | 2,051 | 7,030 | 1,769 |
| 30 Sep 14 | 29,215 | 2,078 | 6,774 | 1,769 |
| 30 Jun 14 | 28,109 | 2,094 | 6,977 | 1,280 |
| 31 Mar 14 | 27,356 | 1,982 | 6,793 | 1,280 |
| 31 Dec 13 | 26,100 | 1,999 | 6,255 | 1,280 |
| 30 Sep 13 | 25,174 | 2,068 | 5,937 | 1,280 |
Quality Earnings: 4554 has a large one-off gain of ¥4.0B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 4554's current net profit margins (12.2%) are higher than last year (7.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4554's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: 4554's earnings growth over the past year (88%) exceeds its 5-year average (2.5% per year).
Earnings vs Industry: 4554 earnings growth over the past year (88%) exceeded the Pharmaceuticals industry 0.6%.
Return on Equity
High ROE: 4554's Return on Equity (12.1%) is considered low.